ATE58294T1 - Pharmazeutische zusammensetzungen. - Google Patents

Pharmazeutische zusammensetzungen.

Info

Publication number
ATE58294T1
ATE58294T1 AT87306297T AT87306297T ATE58294T1 AT E58294 T1 ATE58294 T1 AT E58294T1 AT 87306297 T AT87306297 T AT 87306297T AT 87306297 T AT87306297 T AT 87306297T AT E58294 T1 ATE58294 T1 AT E58294T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
aqueous solution
taurultam
taurolidine
particularly suitable
Prior art date
Application number
AT87306297T
Other languages
English (en)
Inventor
Rolf Wilhelm Pfirrmann
Original Assignee
Geistlich Soehne Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Soehne Ag filed Critical Geistlich Soehne Ag
Application granted granted Critical
Publication of ATE58294T1 publication Critical patent/ATE58294T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT87306297T 1986-07-17 1987-07-16 Pharmazeutische zusammensetzungen. ATE58294T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868617482A GB8617482D0 (en) 1986-07-17 1986-07-17 Pharmaceutical composition
EP87306297A EP0253662B1 (de) 1986-07-17 1987-07-16 Pharmazeutische Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE58294T1 true ATE58294T1 (de) 1990-11-15

Family

ID=10601226

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87306297T ATE58294T1 (de) 1986-07-17 1987-07-16 Pharmazeutische zusammensetzungen.

Country Status (9)

Country Link
EP (1) EP0253662B1 (de)
JP (1) JP2550356B2 (de)
KR (1) KR950009096B1 (de)
AT (1) ATE58294T1 (de)
AU (1) AU604031B2 (de)
CA (1) CA1287300C (de)
DE (1) DE3766175D1 (de)
ES (1) ES2026184T3 (de)
GB (1) GB8617482D0 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614170B2 (en) * 1988-08-26 1991-08-22 Minnesota Mining And Manufacturing Company A steam sensitive composition and a sterilization indicator composition containing the same
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20030027818A1 (en) 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
AU760140B2 (en) * 1997-10-24 2003-05-08 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
FR2771928B1 (fr) * 1997-12-05 2001-04-13 Jean Noel Thorel Composition comprenant des derives de taurine ; son utilisation comme agent conservateur d'un produit alimentaire, ou pharmaceutique, topique ou cosmetique
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US6821968B2 (en) * 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
CN100519525C (zh) 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
JP2003515558A (ja) 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療するためのメチロール含有化合物の使用
WO2003028642A2 (en) 2001-10-01 2003-04-10 Rhode Island Hospital, A Lifespan Partner Methods of inhibiting metastases
RU2468796C2 (ru) 2006-09-07 2012-12-10 Эд. Гайстлих Зёне Аг Фюр Хемише Индустри Способ лечения рака костей
ES2644870T3 (es) 2012-06-18 2017-11-30 Geistlich Pharma Ag Derivados de oxatiazina como agentes antibacterianos y anticancerígenos
EP4011871A3 (de) 2014-12-19 2022-08-24 Geistlich Pharma AG Verfahren zur herstellung von oxathiazinartigen verbindungen
WO2017158570A1 (en) 2016-03-18 2017-09-21 Geistlich Pharma Ag Method of treating triple negative breast cancer
KR20240004303A (ko) 2021-04-29 2024-01-11 가이스틀리히 파마 아게 항균제 및 항암제
WO2024028846A1 (en) 2022-08-05 2024-02-08 Geistlich Pharma Ag Combination therapy for treating cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600878A5 (de) * 1975-04-28 1978-06-30 Gaba Ag
DE2731013C2 (de) * 1977-07-08 1982-07-15 Lentia Gmbh Verfahren zur Herstellung einer wäßrigen Infusionslösung
US4296130A (en) * 1979-08-30 1981-10-20 Herschler R J Methylsulfonylmethane and methods of use
JPS58116413A (ja) * 1981-12-29 1983-07-11 Nippon Kayaku Co Ltd 静注用総合ビタミン剤
GB8328111D0 (en) * 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
JPS60246313A (ja) * 1984-05-22 1985-12-06 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンの注射剤およびその製法

Also Published As

Publication number Publication date
KR950009096B1 (ko) 1995-08-14
DE3766175D1 (de) 1990-12-20
AU7578587A (en) 1988-01-21
JP2550356B2 (ja) 1996-11-06
AU604031B2 (en) 1990-12-06
ES2026184T3 (es) 1992-04-16
EP0253662A1 (de) 1988-01-20
EP0253662B1 (de) 1990-11-14
JPS6372626A (ja) 1988-04-02
GB8617482D0 (en) 1986-08-28
KR880001283A (ko) 1988-04-22
CA1287300C (en) 1991-08-06

Similar Documents

Publication Publication Date Title
DE3766175D1 (de) Pharmazeutische zusammensetzungen.
NO2002009I2 (no) Tiotropium
DE3772924D1 (de) Gegen oxydierung und verfaerbung stabilisierte arzneimittelzubereitungen.
DK543687A (da) Stabiliseret farmaceutisk praeparat
FI914928A0 (fi) Hydroximetyl (metylencyklopentyl) puriner och -pyrimidiner.
ATE72991T1 (de) Nasale verabreichung von arzneimitteln.
ATE169219T1 (de) Behandlung von katarakt mit 15-keto- prostaglandinderivaten
FI892498A0 (fi) Aromatiska och heterocykliska karboxiamidderivat saosom antitumoera aemnen.
ES2093650T3 (es) Una solucion farmaceutica que comprende derivados de fk506.
ES2126636T3 (es) Derivados del bencimidazol con actividad antidiabetica y antiagregante plaquetaria.
ATE75743T1 (de) Hydrazinderivate und ihre verwendung.
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
FI851261A0 (fi) Substituerade bensopyraner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
UA27713C2 (uk) Амідинові похідні бензолу, що мають гіпоглікемічну активність, та їх фармацевтично прийнятні солі
CA1271748C (en) BENZAZEPINE DERIVATIVES
ES2113345T3 (es) Tratamiento de la disfuncion cardiaca con la ayuda de compuestos 15-ceto-prostaglandina.
ATE104149T1 (de) Dialysier- und spuelloesung zur intraperitonealen verarbreichung.
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
ES2109244T3 (es) Medicamentos que contienen compuestos de 3,7-diazabiciclo(3,3,1)nonano.
KR920003972A (ko) 프로스타시클린 화합물을 이용한 백내장 치료
SE8601963D0 (sv) O-sulfated beta-lactam hydroxamic acids
NO911042L (no) Antipsykotiske 4-(4-(3-benzisotiazolyl)-1-piperazinyl)butyl brodannede bicykliske imider.
ATE71380T1 (de) Aminoacylderivate von 4,9-dihydro-10h-pyrido(3,2b>thieno(3,2-e>(1,4>diazepinonen und 4,9-dihydro10h-pyrido(3,2-b>thieno(3,4-e>(1,4>diazepinonen ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
ES2093051T3 (es) Purinil- y pirimidil-tetrahidrofuranos.
DE3852245D1 (de) Isoprenderivate und diese enthaltende Anti-Ulcus-Mittel.